Development of a Screening Tool for the Risk of Vitamin D Deficiency (EvidenceQ)

May 27, 2020 updated by: Hellas Cena, University of Pavia
Since vitamin D deficiency is a condition that affects a high percentage of individuals of all ages and given the attention on the possible role of the deficiency of this vitamin in the development of various chronic diseases, including cardiovascular and metabolic disease (obesity, insulin resistance, hypertension, diabetes) and the correlation with mortality from major cardiovascular events (heart failure, myocardial infarction, sudden cardiac death, stroke, atrial fibrillation and peripheral vascular disease), it is clear that in clinical practice it is necessary to provide screening tools characterized by a simple use, high efficacy and a low economic impact, useful to detect a possible deficiency state that has a significant impact on general health and therefore provide targeted interventions for diagnosis and supplementation when and if necessary. Therefore, the objective of this study project is part of the broader context of supporting, with reproducible and shared scientific data, operational protocols useful for the clinician to identify subjects potentially at risk of vitamin D deficiency as well as directing to the diagnostic and more effective therapeutic. Surveillance of vitamin D status should be a high priority in which easy-to-use and interpreted tools, such as the questionnaire developed for this study, could respond to the needs of early identification of subjects potentially at risk of hypovitaminosis D, thus supporting the work of the clinician.

Study Overview

Detailed Description

It will be administered the questionnaire which includes specific and previously identified questions useful for the purpose of the study to all patients who belong to the clinic of the Dietetics and Clinical Nutrition, Internal Medicine and Endocrinology Unit, ICS Maugeri di Pavia who meet the inclusion criteria and signed the Informed Consent. The blood dosage of 25 (OH) D will be used as a reference standard useful for achieving the purpose of the study subject to the execution of diagnostic-therapeutic procedures that are beneficial to the patient or performed for routine diagnostic procedures or previously prescribed by the general practitioner. The collected data will be entered in the Data Collected Form together with the laboratory tests.

Therefore, all patients will receive the EVIDENCE Questionnaire which includes 19 items that investigate those factors that influence the production, absorption and intake of vitamin D:

  • anthropometric data (weight, height, waist circumference, BMI),
  • demographic information, such as latitude and phototype,
  • dietary intake of vitamin D,
  • health status and therapies,
  • multivitamin or vitamin D supplementation,
  • sun exposure habits according to the season, frequency and time of exposure, the body parts exposed, the sunscreens use and outdoor activities.

The aim of the study is to develop a questionnaire useful in screening the adequacy of vitamin D concentration in the adult population and to produce evidence of construct validity and concurrent validity of the questionnaire itself.

SAMPLE SIZE: Psychometric literature suggests enrolling around 5-10 subjects for each item. Considering the number of items in the questionnaire, equal to 19, the number of subjects to be enrolled will be approximately 190.

Study Type

Observational

Enrollment (Anticipated)

190

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lombardia
      • Pavia, Lombardia, Italy, 27100
        • Recruiting
        • Istituti Clinici Scientifici Maugeri SpA
        • Contact:
        • Sub-Investigator:
          • Chiara Elena Tomasinelli, PhD
        • Sub-Investigator:
          • Rachele De Giuseppe, Lecturer
        • Sub-Investigator:
          • Giorgia Preatoni, Student

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Psychometric literature suggests that about 5-10 subjects should be recruited for each item (Steiner DL et al, 2015). Considering the number of items in the questionnaire, equal to 19, the number of subjects to enlist will be about 190.

Consecutively recruited adult patients by the Service of Dietetics and Clinical Nutrition, Unit of Internal Medicine and Endocrinology, of both sexes.

Description

Inclusion Criteria:

  • Subjects older than or equal 18 years;
  • Absence of liver pathologies;
  • Absence of kidney pathologies;
  • Absence of intestinal malabsorption syndromes;
  • Absence of bariatric surgery;
  • Absence of cancer;
  • Absence of primary hyperparathyroidism;
  • Absence of extensive dermatological pathologies (e.g. psoriasis, atopic dermatitis, vitiligo)
  • Absence of supplementation with multivitamin supplements or vitamin D;
  • Absence of chronic drug therapy with: anticonvulsants, antipsychotics, glucocorticoids, immunosuppressive corticosteroids, anti-retrovirals, slimming, hypocolestrolemicants, laxatives (prolonged use);
  • acceptance and sign of informed consent.

Exclusion Criteria:

  • Subjects under 18 years old;
  • Affected by liver pathologies;
  • Affected by kidney pathologies;
  • Affected by intestinal malabsorption syndromes;
  • Affected by cancer;
  • Affected by primary hyperparathyroidism;
  • Affected by extensive dermatological pathologies (e.g. psoriasis, atopic dermatitis, vitiligo).
  • Candidates and/or undergoing bariatric surgery;
  • Supplementation with multivitamin or vitamin D;
  • Chronic therapy with: anticonvulsants, antipsychotics, glucocorticoids, immunosuppressive corticosteroids, anti-retrovirals, slimming, hypocolestrolemizzanti, laxatives (prolonged use).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
EvidenceQ Cohort
Adult subjects, aged over 18 years, male and female.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Construct validity (EVIDENCE Questionnaire)
Time Frame: 1 hour
The construct validity of the questionnaire will be assessed using exploratory factorial analysis.
1 hour
Internal consistency (EVIDENCE Questionnaire)
Time Frame: 1 hour
The internal consistency will be evaluated with the Cronbach alpha coefficient or with the McDonald Omega coefficient.
1 hour
Concurrent validity (EVIDENCE Questionnaire)
Time Frame: 1 hour
The concurrent validity will be assessed by comparing the results obtained with the serum 25 (OH) D dosage taken as the reference standard.
1 hour
Questionnaire Scoring
Time Frame: 1 hour
Determine the optimal cut-off score of EvidenceQ for screening of subjects potentially at risk of vitamin D inadequacy.
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hellas Cena, Univeristy of Pavia, ICS Maugeri SpA SB

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 14, 2020

Primary Completion (ANTICIPATED)

January 31, 2022

Study Completion (ANTICIPATED)

January 31, 2022

Study Registration Dates

First Submitted

May 18, 2020

First Submitted That Met QC Criteria

May 27, 2020

First Posted (ACTUAL)

May 28, 2020

Study Record Updates

Last Update Posted (ACTUAL)

May 28, 2020

Last Update Submitted That Met QC Criteria

May 27, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vitamin D Deficiency

Subscribe